Inborn errors of metabolism:
Indications for: SCENESSE
To increase pain free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.
Adult Dosage:
See full labeling. Use an SFM implantation cannula or other suitable devices. ≥18yrs: Insert 1 implant subcutaneously above the anterior supra-iliac crest every 2 months.
Children Dosage:
<18yrs: not established.
SCENESSE Warnings/Precautions:
Should be administered by an experienced health care provider. Pre-existing nevi and ephelides. Monitor skin pigmentary lesions; perform full body skin exam twice yearly. Advise patients to maintain sun and light protection measures during treatment to prevent phototoxic reactions. Pregnancy. Nursing mothers.
SCENESSE Classification:
Melanocortin receptor agonist.
Adverse Reactions:
Implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, skin irritation; skin pigmentation/darkening.
Drug Elimination:
Half-life: ~15 hours.
Generic Drug Availability:
NO
How Supplied:
Implant (in vial)—1
